Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
Coagulation01:09

Coagulation

The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
Coagulation01:06

Coagulation

Colloidal solids are solid particles suspended in solution. They are usually negatively charged, attracting a compact primary layer of positively charged ions, which attract more counterions to form an electrical double layer. Electrostatic repulsion between the charged double layers prevents the particles from colliding, stabilizing the colloids. These solids are often undesirable because they can contain toxins that are difficult to remove. Coagulation is a technique that helps aggregate and...
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Introduction to Hemostasis01:05

Introduction to Hemostasis

Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized, and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Removal of tine-based leadless pacemakers - Insights from a large multicenter experience.

Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology·2026
Same author

Integration of PRAETORIAN Score, Defibrillation Testing and Follow-Up Outcomes for the Assessment of Conversion Failure in Patients with Subcutaneous Implantable Cardioverter Defibrillator: results from the i-SUSI registry.

Heart rhythm·2026
Same author

Partner valves: role of a prospective device selection strategy using ACURATE and SAPIEN 3 as complementary devices in transcatheter aortic valve implantation.

Frontiers in cardiovascular medicine·2026
Same author

Reclassification of Exercise-Induced Arrhythmogenic Cardiomyopathy: Detection of a Pathogenic PKP2 Variant in a Male Athlete.

JACC. Case reports·2026
Same author

Electromagnetic interference during epicardial ablation in a patient with an extravascular implantable cardioverter-defibrillator and arrhythmogenic right ventricular cardiomyopathy: a case report.

European heart journal. Case reports·2026
Same author

Neural resilience improves survival in cardiovascular patients.

Cardiovascular research·2026

Related Experiment Video

Updated: Jun 19, 2026

Extracellular Vesicle Tissue Factor Activity Assay
03:53

Extracellular Vesicle Tissue Factor Activity Assay

Published on: December 29, 2023

Tissue factor: beyond coagulation in the cardiovascular system.

Alexander Breitenstein1, Giovanni G Camici, Felix C Tanner

  • 1Cardiovascular Research, Physiology Institute, University of Zurich, Zurich, Switzerland.

Clinical Science (London, England : 1979)
|October 23, 2009
PubMed
Summary
This summary is machine-generated.

Tissue factor (TF) initiates blood coagulation and contributes to cardiovascular disease. Inhibiting TF is a promising therapeutic strategy for treating thrombosis and atherosclerosis.

More Related Videos

Flow Cytometry Analysis of Tissue Factor Expression in Human Platelets
10:08

Flow Cytometry Analysis of Tissue Factor Expression in Human Platelets

Published on: November 22, 2024

A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time
09:38

A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time

Published on: February 14, 2017

Related Experiment Videos

Last Updated: Jun 19, 2026

Extracellular Vesicle Tissue Factor Activity Assay
03:53

Extracellular Vesicle Tissue Factor Activity Assay

Published on: December 29, 2023

Flow Cytometry Analysis of Tissue Factor Expression in Human Platelets
10:08

Flow Cytometry Analysis of Tissue Factor Expression in Human Platelets

Published on: November 22, 2024

A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time
09:38

A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time

Published on: February 14, 2017

Area of Science:

  • Biochemistry
  • Cardiovascular Biology
  • Molecular Medicine

Background:

  • Tissue factor (TF) is a key initiator of the coagulation cascade, leading to fibrin formation.
  • TF expression is induced by various stimuli in vascular cells and is detectable in the bloodstream as circulating TF.
  • Cardiovascular risk factors like hypertension and diabetes are linked to increased TF expression.

Purpose of the Study:

  • To review the role of tissue factor in coagulation and cardiovascular disease.
  • To highlight TF's pro-atherogenic properties, including its role in neointima formation.
  • To discuss therapeutic strategies targeting TF for cardiovascular disease treatment.

Main Methods:

  • Literature review of TF's role in coagulation and cardiovascular pathology.
  • Analysis of TF's involvement in signaling pathways (MAPKs, PI3K, PKC).
  • Examination of TF's association with cardiovascular risk factors and acute coronary syndromes.

Main Results:

  • TF triggers fibrin formation by activating Factor IX and X via Factor VIIa.
  • Elevated circulating TF levels are observed in cardiovascular risk factors and acute coronary syndromes.
  • TF promotes atherosclerosis by inducing vascular smooth muscle cell migration.

Conclusions:

  • TF is a critical mediator in both thrombosis and atherosclerosis.
  • Inhibiting TF action presents a potential therapeutic avenue for cardiovascular diseases.
  • TF pathway inhibitor (TFPI) modulation is also being investigated for therapeutic benefit.